Rheumatology Advance Access published online on June 6, 2007
Rheumatology, doi:10.1093/rheumatology/kem133
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK
HEDS, Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield S1 4DA, 1Wyeth Pharmaceuticals, Taplow, Maidenhead, Berks SL6 0PH, UK
Correspondence to:
R. M. Ara, Health Economics and Decision Science, ScHARR, University of Sheffield, Regent Court, 40 Regent Street, Sheffield S1 4DA, UK. E-mail: r.m.ara{at}sheffield.ac.uk
 |
Abstract |
|---|
Objectives. To examine the costs and benefits associated with long-term etanercept (ETN) treatment in patients with severe ankylosing spondylitis (AS) in the UK in accordance with the BSR guidelines.
Methods. A mathematical model was constructed to estimate the costs and benefits associated with ETN plus non-steroidal anti-inflammatory drugs (NSAIDs) compared with NSAIDs alone. Individual patient data from Phase III RCTs was used to inform the proportion and magnitude of initial response to treatment and changes in health-related quality of life. A retrospective costing exercise on patients attending a UK secondary care rheumatology unit was used to inform disease costs. Published evidence on long-term disease progression was extrapolated over a 25-yr horizon. Uncertainty was examined using probabilistic sensitivity analyses.
Results. Over a 25-yr horizon, ETN plus NSAIDs gave 1.58 more QALYs at an additional cost of £35 978 when compared with NSAID treatment alone. This equates to a central estimate of £22 700 per QALY. The incremental cost per QALYs using shorter time periods were £27 600, £23 600 and £22 600 at 2, 5 and 15 yrs, respectively. Using a 25-yr horizon, 93% of results from the probabilistic analyses fall below a threshold of £25 000 per QALY.
Conclusions. This study demonstrates the potential cost-effectiveness of ETN plus NSAIDs compared with NSAIDs alone in patients with severe AS treated according to the BSR guidelines in the UK.
KEY WORDS: Tumour necrosis factor, Health status, Cost effectiveness, Cost utility, Economic evaluation, Ankylosing spondylitis
Submitted 31 August 2006;
revised version accepted 11 April 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Wailoo, N. Bansback, and J. Chilcott Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance Rheumatology, February 1, 2008; 47(2): 119 - 120. [Full Text] [PDF]
|
|